Allosteric transition: A comparison of two models

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Bindslev, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERIC TWO STATE MODEL; ALLOSTERISM; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONFORMATION; EXTENDED OPERATIONAL MODEL; INTERMETHOD COMPARISON; LIGAND BINDING; MODEL; SIMULATION; CHEMICAL STRUCTURE; METABOLISM;

CELL SURFACE RECEPTOR; DRUG; LIGAND;

ALLOSTERIC SITE; LIGANDS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CELL SURFACE;

MLCS; MLOWN;

EID: 84879835462     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-4     Document Type: Article

References (60)

1. Ledford H. Drug buddies. Nature 2011, 474:433-434. 10.1038/474433a, 21697923.
2. Macilwain C. Pharmaceutical industry must take its medicine. Nature 2011, 470:141. 10.1038/470141a, 21307893.
3. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012, 11:191-200. 10.1038/nrd3681, 22378269.
4. Elsinghorst PW, Härtig W, Gündisch D, Mohr K, Tränkle C, Gütschow M. A hydrazide linker strategy for heterobivalent compounds as ortho- and allosteric ligands of acetylcholine-binding proteins. Curr Top Med Chem 2011, 11:2731-2748. 10.2174/156802611798184427, 22039876.
5. Gao ZG, Verzijl D, Zweemer A, Ye K, Göblyös A, Ijzerman AP. Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol 2011, 82:658-668. 10.1016/j.bcp.2011.06.017, 3152598, 21718691.
6. Jensen PC, Thiele S, Steen A, Elder A, Kolbeck R, Ghosh S. Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2. Br J Pharmacol 2012, 166:258-275. 10.1111/j.1476-5381.2011.01771.x, 3415653, 22050085.
7. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 2012, 55:1445-1464. 10.1021/jm201139r, 3349997, 22148748.
8. Valant C, Felder CC, Sexton PM, Christopoulos A. Probe dependence in the allosteric modulation of a G protein-coupled receptor: Implications for detection and validation of allosteric ligand effects. Mol Pharmacol 2012, 81:41-52. 10.1124/mol.111.074872, 21989256.
9. Audet M, Lagacé M, Silversides DW, Bouvier M. Protein-protein interactions monitored in cells from transgenic mice using bioluminescence resonance energy transfer. FASEB J 2010, 24:2829-2838. 10.1096/fj.09-144816, 20335229.
10. Chung KY, Rasmussen SG, Liu T, Li S, Devree BT, Chae PS. Conformational changes in the G protein Gs induced by the ß2 adrenergic receptor. Nature 2011, 477:611-615. 10.1038/nature10488, 3448949, 21956331.
11. Comps-Agrar L, Kniazeff J, Nørskov-Lauritsen L, Maurel D, Gassmann M, Gregor N. The oligomeric state sets GABA(B) receptor signalling efficacy. EMBO J 2011, 30:2336-2349. 10.1038/emboj.2011.143, 3116278, 21552208.
12. Henderson BJ, Orac CM, Maciagiewicz I, Bergmeier SC, McKay DB. 3D-QSAR and 3D-QSSR models of negative allosteric modulators facilitate the design of a novel selective antagonist of human a4ß2 neuronal nicotinic acetylcholine receptors. Bioorg Med Chem Lett 2012, 22:1797-1813. 10.1016/j.bmcl.2011.11.051, 3274641, 22285942.
13. Nygaard R, Valentin-Hansen L, Mokrosinski J, Frimurer TM, Schwartz TW. Conserved water-mediated hydrogen bond network between TM-I, -II, -VI, and -VII in 7TM receptor activation. J Biol Chem 2010, 285:19625-19636. 10.1074/jbc.M110.106021, 2885241, 20395291.
14. Peeters MC, Wisse LE, Dinaj A, Vroling B, Vriend G, Ijzerman AP. The role of the second and third extracellular loops of the adenosine A1 receptor in activation and allosteric modulation. Biochem Pharmacol 2012, 84:76-87. 10.1016/j.bcp.2012.03.008, 22449615.
15. Schelshorn DW, Joly F, Mutel S, Hampe C, Breton B, Mutel V. Lateral Allosterism in the Glucagon Receptor Family: GLP-1 Induces GPCR Heteromer Formation. Mol Pharmacol 2012, 81:309-318. 10.1124/mol.111.074757, 22108912.
16. Van Eps N, Preininger AM, Alexander N, Kaya AI, Meier S, Meiler J. Interaction of a G protein with an activated receptor opens the interdomain interface in the alpha subunit. Proc Natl Acad Sci USA 2011, 108:9420-9424. 10.1073/pnas.1105810108, 3111277, 21606326.
17. Keov P, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 2011, 60:24-35. 10.1016/j.neuropharm.2010.07.010, 20637785.
18. Bindslev N. Drug-Acceptor Interactions. Modeling Theoretical Tools to Test and Evaluate Experimental Equilibrium Effects 2008, Stockholm: Co-Action Publishing, 1.
19. De Amici M, Dallanoce C, Holzgrabe U, Tränkle C, Mohr K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev 2010, 30:463-549.
20. Ehlert FJ, Griffin MT. Two-state models and the analysis of the allosteric effect of gallamine at the m2 muscarinic receptor. J Pharmacol Exp Ther 2008, 325:1039-1060. 10.1124/jpet.108.136960, 18305010.
21. Gomes I, Ijzerman AP, Ye K, Maillet EL, Devi LA. G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 2011, 79:1044-1052. 10.1124/mol.110.070847, 3102551, 21415307.
22. Hall DA. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 2000, 58:1412-1423.
23. Jäger D, Schmalenbach C, Prilla S, Schrobang J, Kebig A, Sennwitz M. Allosteric small molecules unveil a role of an extracellular E2/transmembrane helix 7 junction for G protein-coupled receptor activation. J Biol Chem 2007, 30:34968-34976.
24. Kenakin TP. '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 2009, 30:460-469. 10.1016/j.tips.2009.06.007, 19729207.
25. Stahl E, Elmslie G, Ellis J. Allosteric modulation of the M3 muscarinic receptor by amiodarone and N-ethylamiodarone: application of the four-ligand allosteric two-state model. Mol Pharmacol 2011, 80:378-388. 10.1124/mol.111.072991, 3164337, 21602476.
26. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Supplementary data. Trends Pharmacol Sci 2007, 28:382-389. 10.1016/j.tips.2007.06.004, 17629965.
27. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B 1983, 220:141-162. 10.1098/rspb.1983.0093, 6141562.
28. Ross EM, Maguire ME, Sturgill TW, Biltonen RL, Gilman AG. Relationship between the beta-adrenergic receptor and adenylate cyclase. J Biol Chem 1977, 252:5761-5775.
29. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist specific binding properties of the adenylate cyclase coupled beta- adrenergic receptor. J Biol Chem 1980, 255:7108-7117.
30. Stockton JM, Birdsall NJ, Burgen AS, Hulme EC. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983, 23:551-557.
31. Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 1988, 33:187-194.
32. Bradley SJ, Langmead CJ, Watson JM, Challiss RA. Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. Mol Pharmacol 2011, 79:874-885. 10.1124/mol.110.068882, 3082933, 21321061.
33. Canals M, Lane JR, Wen A, Scammells PJ, Sexton PM, Christopoulos A. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J Biol Chem 2012, 287:650-659. 10.1074/jbc.M111.314278, 3249119, 22086918.
34. Kenakin TP. Biased signaling and allosteric machines; new vistas and challenges for drug discovery. Br J Pharmacol 2012, 165:1659-1669. 10.1111/j.1476-5381.2011.01749.x, 3372820, 22023017.
35. Leach K, Davey AE, Felder CC, Sexton PM, Christopoulos A. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. Mol Pharmacol 2011, 79:855-865. 10.1124/mol.111.070938, 21300722.
36. Smith NJ, Ward RJ, Stoddart LA, Hudson BD, Kostenis E, Ulven T. Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol 2011, 80:163-173. 10.1124/mol.110.070789, 3127537, 21498659.
37. Suratman S, Leach K, Sexton P, Felder C, Loiacono R, Christopoulos A. Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br J Pharmacol 2011, 162:1659-1670. 10.1111/j.1476-5381.2010.01184.x, 3057301, 21198541.
38. Wootten D, Savage EE, Valant C, May LT, Sloop KW, Ficorilli J. Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Mol Pharmacol 2012, 82:281-290. 10.1124/mol.112.079319, 22576254.
39. Birdsall NJ. Class A GPCR heterodimers: evidence from binding studies. Trends Pharmacol Sci 2010, 31:499-508. 10.1016/j.tips.2010.08.003, 20870299.
40. Jakubík J, Janícková H, El-Fakahany EE, Doležal V. Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy. Br J Pharmacol 2011, 162:1029-1044. 10.1111/j.1476-5381.2010.01081.x, 3051377,3051377, 20958290.
41. Kiselyov VV, Versteyhe S, Gauguin L, De Meyts P. Harmonic oscillator model of the insulin and IGF1 receptors' allosteric binding and activation. Mol Syst Biol 2009, 5:1-12.
42. Rovira X, Roche D, Serra J, Kniazeff J, Pin JP, Giraldo J. Modeling the binding and function of metabotropic glutamate receptors. J Pharmacol Exp Ther 2008, 325:443-456. 10.1124/jpet.107.133967, 18287211.
43. Birnbaumer L, Bearer CF, Iyengar R. A two-state model of an enzyme with an allosteric regulator site capable of metabolizing the regulatory ligand. J Biol Chem 1980, 255:3552-3557.
44. Leff P. The twostate model of receptor activation. Trends Pharmacol Sci 1995, 16:89-97. 10.1016/S0165-6147(00)88989-0, 7540781.
45. Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956, 11:379-393.
46. Changeux JP. Allosteric proteins: from regulatory enzymes to receptors - personal recollections. Bioessays 1993, 15:625-634. 10.1002/bies.950150909, 8240316.
47. Monod J, Wyman J, Changeux J-P. On the nature of allosteric transitions: a plausible model. J Mol Biol 1965, 12:88-118. 10.1016/S0022-2836(65)80285-6, 14343300.
48. Changeux JP. 50th anniversary of the word "allosteric". Protein Sci 2011, 20:1119-1124. 10.1002/pro.658, 3149185, 21574197.
49. Koshland DE. Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci 1958, 44:98-104. 10.1073/pnas.44.2.98, 335371, 16590179.
50. Katz B, Thesleff S. A study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol 1957, 138:63-80. 1363030, 13463799.
51. Furchgott RF. Receptor mechanisms. Ann Rev Pharmcol 1964, 4:21-50.
52. Furchgott RF. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res 1966, 3:21-55.
53. Kenakin TP, Beek D. Is prenalterol (H133/80) really a selective beta 1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships. J Pharmacol Exp Ther 1980, 213:406-413.
54. Slack RJ, Hall DA. Development of operational models of receptor activation including constitutive receptor activity and their use to determine the efficacy of the chemokine TARC at the CC-chemokine receptor CCR4. Br J Pharmacol 2012, 166:1774-1792. 10.1111/j.1476-5381.2012.01901.x, 22335621.
55. Ehlert FJ, Suga H, Griffin MT. Analysis of agonism and inverse agonism in functional assays with constitutive activity: estimation of orthosteric ligand affinity constants for active and inactive receptor states. J Pharmacol Exp Ther 2011, 338:671-686. 10.1124/jpet.111.179309, 3141894, 21576379.
56. Perdona E, Costantini VJ, Tessari M, Martinelli P, Carignani C, Valerio E. In vitro and in vivo characterization of the novel GABAB receptor positive allosteric modulator, 2-{1-[2-(4-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-2-piperidinyl}ethanol (CMPPE). Neuropharmacology 2011, 61:957-966. 10.1016/j.neuropharm.2011.06.024, 21756923.
57. Hall DA, Langmead CJ. Matching models to data: a receptor pharmacologist's guide. Br J Pharmacol 2010, 161:1276-1290. 10.1111/j.1476-5381.2010.00879.x, 3000653, 20977467.
58. Segel IH. Enzyme kinetics. Behavior and analysis of rapid equilibrium and steady-state enzyme systems 1975, New York: Wiley & Sons, reissued 1993.
59. Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR. Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol Pharmacol 2009, 75:44-59. 10.1124/mol.108.049189, 18923064.
60. Mueller R, Dawson ES, Meiler J, Rodriguez AL, Chauder BA, Bates BS. Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5): from an artificial neural network virtual screen to an in vivo tool compound. ChemMedChem 2012, 7:406-414. 10.1002/cmdc.201100510, 3517057, 22267125.